Although the allicin treatment prevented the increase in HIF-1α and VEGF in comparison with the diabetic group (Figure 8a,b), this treatment further increased Epo and Epo-R without statistical difference between both groups of diabetes (Figure 8c,d). This evidence concerns the gene VEGFA and diabetes mellitus.